Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Al Cancer - Overview
Al Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Al Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Al Cancer - Companies Involved in Therapeutics Development
Al Cancer - Drug Profiles
Al Cancer - Dormant Projects
Al Cancer - Discontinued Products
Al Cancer - Product Development Milestones
Featured News & Press Releases
Dec 06, 2021: PDS Biotech provides recruitment update for tiol Cancer Institute-Led phase 2 clinical trial of PDS0101-based combition
Oct 15, 2021: Zynyz: Withdrawal of the marketing authorisation application
Jul 23, 2021: Incyte provides regulatory update on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the al cal (SCAC)
Jun 24, 2021: Incyte announces outcome of FDA Oncologic Drugs Advisory Committee (ODAC) meeting reviewing retifanlimab as a treatment for patients with Squamous Cell Carcinoma of the Al Cal (SCAC)
Jun 24, 2021: Transgene: First patient enrolled in expanded phase II clinical trial of TG4001 + avelumab Vs avelumab alone in patients With HPV16-positive anogenital cancers
Mar 10, 2021: Transgene expands phase II clinical trial of therapeutic vaccine TG4001 in combition with Avelumab versus Avelumab monotherapy in patients with HPV16-positive anogenital cancers
Feb 26, 2021: Incyte announces the validation by the European Medicines Agency of its marketing authorization application for retifanlimab as a treatment for patients with squamous cell al carcinoma (SCAC)
Nov 30, 2020: MacroGenics announces achievement of $25 million in milestones related to retifanlimab collaboration with Incyte
Apr 08, 2019: Inovio achieves third cancer indication milestone for MEDI0457 phase 2 development
Apr 03, 2019: MacroGenics reports presentation of data on MGA-012 at the AACR Annual Meeting 2019
Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
Sep 11, 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer
Nov 08, 2016: Dr. Shepard, CMO Of PDS Biotechnology, To Present PDS0101 Phase I/IIA Clinical Data At The Society For Immunotherapy Of Cancer Meeting On November 11, 2016
Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic al cancer
Dec 07, 2015: ISA Pharmaceuticals’ ISA101 Studied in Phase II Combition Trial with Checkpoint Inhibitor Nivolumab
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Anal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Anal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Anal Cancer - Pipeline by Antiva Biosciences Inc, 2022
Anal Cancer - Pipeline by AstraZeneca Plc, 2022
Anal Cancer - Pipeline by Beijing Corregene Biotechnology Co Ltd, 2022
Anal Cancer - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
Anal Cancer - Pipeline by Bicara Therapeutics Inc, 2022
Anal Cancer - Pipeline by Biomimetix JV LLC, 2022
Anal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
Anal Cancer - Pipeline by Cue Biopharma Inc, 2022
Anal Cancer - Pipeline by CytomX Therapeutics Inc, 2022
Anal Cancer - Pipeline by Eisai Co Ltd, 2022
Anal Cancer - Pipeline by Eli Lilly and Co, 2022
Anal Cancer - Pipeline by EpimAb Biotherapeutics Inc, 2022
Anal Cancer - Pipeline by eTheRNA Immunotherapies NV, 2022
Anal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Anal Cancer - Pipeline by Fujifilm Holdings Corp, 2022
Anal Cancer - Pipeline by Genexine Inc, 2022
Anal Cancer - Pipeline by Genocea Biosciences Inc, 2022
Anal Cancer - Pipeline by Gilead Sciences Inc, 2022
Anal Cancer - Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2022
Anal Cancer - Pipeline by HaloVax, 2022
Anal Cancer - Pipeline by Hookipa Pharma Inc, 2022
Anal Cancer - Pipeline by IMV Inc, 2022
Anal Cancer - Pipeline by Incyte Corp, 2022
Anal Cancer - Pipeline by Invectys SA, 2022
Anal Cancer - Pipeline by ISA Pharmaceuticals BV, 2022
Anal Cancer - Pipeline by Merck & Co Inc, 2022
Anal Cancer - Pipeline by Merck KGaA, 2022
Anal Cancer - Pipeline by Mereo Biopharma Group Plc, 2022
Anal Cancer - Pipeline by Molecular Partners AG, 2022
Anal Cancer - Pipeline by Nektar Therapeutics, 2022
Anal Cancer - Pipeline by Novartis AG, 2022
Anal Cancer - Pipeline by Oncolytics Biotech Inc, 2022
Anal Cancer - Pipeline by Onconova Therapeutics Inc, 2022
Anal Cancer - Pipeline by Oncorus Inc, 2022
Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Anal Cancer - Pipeline by PDS Biotechnology Corp, 2022
Anal Cancer - Pipeline by Precigen Inc, 2022
Anal Cancer - Pipeline by Privo Technologies Inc, 2022
Anal Cancer - Pipeline by Repertoire Immune Medicines Inc, 2022
Anal Cancer - Pipeline by Rubius Therapeutics Inc, 2022
Anal Cancer - Pipeline by Sanofi, 2022
Anal Cancer - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Anal Cancer - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Anal Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022
Anal Cancer - Pipeline by Shattuck Labs Inc, 2022
Anal Cancer - Pipeline by SinoCelltech Group Ltd, 2022
Anal Cancer - Pipeline by SOTIO Biotech AS, 2022
Anal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
Anal Cancer - Pipeline by Statera Biopharma Inc, 2022
Anal Cancer - Pipeline by Transgene SA, 2022
Anal Cancer - Pipeline by Treadwell Therapeutics Inc, 2022
Anal Cancer - Pipeline by TScan Therapeutics Inc, 2022
Anal Cancer - Pipeline by Turnstone Biologics Inc, 2022
Anal Cancer - Pipeline by Virion Therapeutics LLC, 2022
Anal Cancer - Pipeline by Xencor Inc, 2022
Anal Cancer - Pipeline by Y-Biologics Inc, 2022
Anal Cancer - Pipeline by Zymeworks Inc, 2022
Anal Cancer - Dormant Projects, 2022
Anal Cancer - Dormant Projects, 2022 (Contd..1)
Anal Cancer - Discontinued Products, 2022